Evidence map›Paper›PMID 36717031›Full record

ArticleJournal of affective disorders2023

Maternal FGF2 levels associated with child anxiety and depression symptoms through child FGF2 levels.

Eli R Lebowitz, Carla E Marin, Meital Orbach, Natalina Salmaso, Flora M Vaccarino, Wendy K Silverman

Open access · greenAbstract read
In one paragraph

Article in Journal of affective disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Eli R LebowitzChild Study Center, Yale School of Medicine, New Haven, CT 06510, USA; Anxiety and Mood Disorders Program, Yale School of Medicine, New Haven, CT 06510, USA. Electronic address: eli.lebowitz@yale.edu.
Carla E MarinChild Study Center, Yale School of Medicine, New Haven, CT 06510, USA; Anxiety and Mood Disorders Program, Yale School of Medicine, New Haven, CT 06510, USA.
Meital OrbachChild Study Center, Yale School of Medicine, New Haven, CT 06510, USA; Anxiety and Mood Disorders Program, Yale School of Medicine, New Haven, CT 06510, USA.
Natalina SalmasoDepartment of Neuroscience, Carleton University, Ottawa, Ontario K1S 5B6, Canada.
Flora M VaccarinoChild Study Center, Yale School of Medicine, New Haven, CT 06510, USA; Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA; Program in Neurodevelopment and Regeneration, Yale University, New Haven, CT 06510, USA.
Wendy K SilvermanChild Study Center, Yale School of Medicine, New Haven, CT 06510, USA; Anxiety and Mood Disorders Program, Yale School of Medicine, New Haven, CT 06510, USA; Department of Psychology, Yale University, New Haven, CT 06520, USA.
Yale University · USCarleton University · CA

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Brain response associated with parent-based treatment for childhood anxiety disordersR61MH115113 · NIMH · YALE UNIVERSITY · PI GEE, DYLAN GRACE, LEBOWITZ, ELI · 2018 to 2019
$1.5M
Fibroblast Growth Factor 2's role in Fear and Approach Motivation in Anxious and Depressed Children and their MothersR21MH113946 · NIMH · YALE UNIVERSITY · PI LEBOWITZ, ELI, SILVERMAN, WENDY K. · 2017 to 2018
$461k
NCATS NIH HHS UL1 TR001863NIMH NIH HHS R21 MH113946NIMH NIH HHS R61 MH115113
6 · The paper itself

Abstract

backgroundRecent research implicates fibroblast growth factor 2 (FGF2) in anxiety and depressive symptoms of childhood. This study is the first to examine an intergenerational pathway linking FGF2 levels in mothers to FGF2 levels in children, and to the children's anxiety and depressive symptoms.

methodsWe assayed serum FGF2 in 259 mothers and their children, with a range of anxiety and depressive symptoms: 194 were mothers of clinic-referred anxious and depressed children; 65 were mothers of non-referred children. We examined associations between FGF2 levels in mothers and children, and anxiety and depression symptoms. We used structural equation modeling (SEM) to examine associations between maternal and child FGF2 levels, and between maternal and child FGF2 levels and symptoms of anxiety and depression in and children.

resultsFGF2 levels in mothers and children were significantly positively correlated. Children's FGF2 levels were significantly negatively correlated with their ratings of anxiety and depression. Results of the SEM model showed that increases in maternal FGF2 levels were significantly associated with increases in child FGF2, which in turn was associated with decreases in child anxiety and child depression, controlling for maternal anxiety and depression. LIMITATIONS: We relied on self-reported ratings of anxiety and depression, and on a single measurement of FGF2 levels for each participant.

conclusionsOur results point to a role for FGF2 in the intergenerational transmission of risk for, and resilience to, anxiety and depression in youth.

Indexed as

DepressionFibroblast Growth Factor 2AdolescentAnxietyAnxiety DisordersChildFemaleHumansMother-Child RelationsMothersFibroblast Growth Factor 2AnxietyChildrenDepressionFibroblast growth factor 2

Identifiers

PMID36717031
PMCPMC10104478
OpenAlexW4318317769

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.